This is the Scientific Surgery Archive, which contains all randomized clinical trials in surgery that have been identified by searching the top 50 English language medical journal issues since January 1998. Compiled by Jonothan J. Earnshaw, former Editor-in-Chief, BJS

Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor–positive, node-positive early breast cancer: final results of the randomized phase III Femara versus Anastrozole Clinical Evaluation (FACE) Trial. J Clin Oncol 2017; 35: 1041-1048.

Published: 30th September 2017

Authors: Smith I, Yardley D, Burris H, De Boer R, Amadori D, McIntyre K et al.

Conclusion

Letrozole had no survival advantage compared to anastrozole in this study that included 4136 women: 5-year disease-free survival hazard ratio 0.93, 95 per cent confidence interval 0.8 to 1.07 and 5-year overall survival 0.98, 0.82 to 1.17.

You may also be interested in

Scientific Surgery

Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer. N Engl J Med 2021; 385: 395-405.

Authors: Gnant M, Fitzal F, Rinnerthaler G, Steger GS, Greil-Ressler S, Balic M et al.

Scientific Surgery

Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 2021; 384: 2394-2405.

Authors: Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P et al.

Scientific Surgery

Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment. The SYSUCC-001 Randomized Clinical Trial. JAMA 2021; 325: 50-58.

Authors: Wang X, Wang S-S, Huang H, Cai L, Peng R-J, Lin Y et al.

Scientific Surgery

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised double-blind, phase 3 trial. Lancet 2020; 396: 1090-1100.

Authors: Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R et al.

Scientific Surgery

Efficacy and safety of tailored and dose‐dense adjuvant chemotherapy and trastuzumab for resected HER2‐positive breast cancer: Results from the phase 3 PANTHER trial. Cancer 2020; 126: 1175-1182.

Authors: Papakonstantinou A, Matikas A, Bengtsson NO, Malmstrom P, Hedayati E, Steger G et al.

Scientific Surgery

Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307. J Natl Cancer Inst 2020; 112: 698-707.

Authors: Gralow JR, Barlow WE, Paterson AHG, M’iao JL, Lew DL, Stopeck AT et al.

Scientific Surgery

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-forward): 5-year efficacy and late normal tissue effects results from a multicenter, non-inferiority, randomised, phase 3 trial. Lancet 2020; 395: 1613-1626.

Authors: Brunt AM, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield DJ et al.

Scientific Surgery

The effects of ganglioside-monosialic acid in taxane-induced peripheral neurotoxicity in patients with breast cancer: a randomized trial. J Natl Cancer Inst 2020; 112: 55–62

Authors: Su Y, Huang J, Wang S, Unger JM, Arias-Fuenzalida J, Shi Y et al.

Scientific Surgery

Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative breast cancer (CBCSG‐036): A randomized, controlled, multicenter trial. Cancer 2019; 125: 2185-2193

Authors: Yu K-D, Wu S-Y, Liu G-Y, Wu J, Di G-H, Hu Z et al.

Scientific Surgery

West German Study Plan B Trial: adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer. J Clin Oncol 2019; 37: 799-808

Authors: Nitz M, Gluz O, Clemens M, Malter W, Reimer T, Nuding B et al.

Scientific Surgery

Pembrolizumab for early triple-negative breast cancer. N Engl J Med 2020; 382: 810-821

Authors: Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J et al.

Scientific Surgery

External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node negative breast cancer (RAPID): a randomized controlled trial. Lancet 2019; 394: 2165-2172

Authors: Whelan TJ, Julian JA, Berrang TS, Kim D-H, Germain I, Nichol AM et al.